Facebook Inc. (NASDAQ:FB) , operates a social networking website worldwide. This Zacks Rank #1, Strong Buy, stock with a Growth score of ‘A’, has ample growth catalysts. Not the least of which are earnings estimates that continue to rise. A strong balance sheet and significant cash flow also make it attractive for investors.
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) , discovers, develops and markets small molecule drugs that address major unmet medical needs. This company has two cystic fibrosis drugs in its portfolio with blockbuster potential. The company also has a strong history of beating consensus earnings estimates. It’s not only a Zacks Rank #1, Strong Buy, but has both Growth and Momentum scores of ‘A’.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Facebook, Inc. (FB): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Original post
Zacks Investment Research